Vaxart (VXRT) Proxy filing summary

Executive summary

• Company is at a pivotal strategic juncture, emphasizing urgency in advancing its oral vaccine platform and achieving clinical and operational milestones.

• Focus on demonstrating the value and potential of oral vaccine delivery to create shareholder value.

• Forward-looking statements highlight expectations for clinical trial results, regulatory approvals, and strategic partnerships.

• Risks include regulatory uncertainties, manufacturing challenges, and capital resource adequacy.

Voting matters and shareholder proposals

• Shareholders are urged to vote "FOR" all six board-nominated directors using the White proxy card and to withhold votes on shareholder nominees.

• Emphasis on the importance of this year's vote due to the company's critical phase and upcoming milestones.

Board of directors and corporate governance

• Board and management team are described as highly qualified and purpose-built to lead through the current strategic period.

• Board composition is positioned as essential for executing key priorities and delivering shareholder value.